Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance

References

• Balzeau, J., M. R. Menezes, S. Cao, and J. P. Hagan. 2017. The lin28/let-7 pathway in cancer. Front Genet 8:31. doi:10.3389/fgene.2017.00031.
   PubMed Web of Science ®Google Scholar
• Bartel, D. P. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281–97. doi:10.1016/S0092-8674(04)00045-5.
   PubMed Web of Science ®Google Scholar
• Bouyssou, J. M., C. J. Liu, M. Bustoros, R. Sklavenitis-Pistofidis, Y. Aljawai, S. Manier, A. Yosef, A. Sacco, K. Kokubun, S. Tsukamoto, et al. 2018. Profiling of circulating exosomal miRNAs in patients with Waldenstrom macroglobulinemia. PLoS ONE 13:e0204589. doi:10.1371/journal.pone.0204589.
   PubMed Web of Science ®Google Scholar
• Calvo, K. R., O. Landgren, A. M. Roccaro, and I. M. Ghobrial 2011. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin. Hematol. 48: 39–45.
   PubMed Web of Science ®Google Scholar
• Corney, D. C., C. I. Hwang, A. Matoso, M. Vogt, A. Flesken-Nikitin, A. K. Godwin, A. A. Kamat, A. K. Sood, L. H. Ellenson, H. Hermeking, et al. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. Cancer Res. 2010 (16):1119–28.
   Google Scholar
• Dispenzieri, A., J. A. Katzmann, R. A. Kyle, D. R. Larson, L. J. Melton, C. L. Colby, T. M. Therneau, R. Clark, S. K. Kumar, A. Bradwell, et al. 2010. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet 375:1721–28. doi:10.1016/S0140-6736(10)60482-5.
   PubMed Web of Science ®Google Scholar
• Etheridge, A., I. Lee, L. Hood, D. Galas, and K. Wang. 2011. Extracellular microRNA: A new source of biomarkers. Mutat. Res. 717:85–90. doi:10.1016/j.mrfmmm.2011.03.004.
   PubMed Web of Science ®Google Scholar
• Federico C., A. Sacco, A. Belotti, R. Ribolla, V. Cancelli, A. Giacomini, R. Ronca, M. Chiarini, L. Imberti, M. Marini, et al. 2019. Circulating microRNAs and their role in multiple myeloma. Non-coding RNA 5. doi:10.3390/ncrna5020037.
   Web of Science ®Google Scholar
• Feng, S., Z. Cao, and X. Wang. 2013. Role of aryl hydrocarbon receptor in cancer. Biochim. Biophys. Acta 1836:197–210. doi:10.1016/j.bbcan.2013.05.001.
   PubMed Web of Science ®Google Scholar
• Gallardo, E., A. Navarro, N. Vinolas, R. M. Marrades, T. Diaz, B. Gel, A. Quera, E. Bandres, J. Garcia-Foncillas, J. Ramirez, et al. 2009. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30:1903–09. doi:10.1093/carcin/bgp219.
   PubMed Web of Science ®Google Scholar
• Ghanbari, R., N. Mosakhani, V. K. Sarhadi, G. Armengol, N. Nouraee, A. Mohammadkhani, S. Khorrami, E. Arefian, M. Paryan, and R. Malekzadeh, et al. 2016. Simultaneous underexpression of let-7a-5p and let-7f-5p micrornas in plasma and stool samples from early stage colorectal carcinoma. Biomark. Cancer. 7 (Suppl 1):39–48. doi: 10.4137/BIC.S25252.
   PubMedGoogle Scholar
• Gilad, S., E. Meiri, Y. Yogev, S. Benjamin, D. Lebanony, N. Yerushalmi, H. Benjamin, M. Kushnir, H. Cholakh, N. Melamed, et al. 2008. Serum microRNAs are promising novel biomarkers. PLoS ONE 3 (9):e3148. doi:10.1371/journal.pone.0003148.
   PubMed Web of Science ®Google Scholar
• Grasedieck, S., A. Sorrentino, C. Langer, C. Buske, H. Döhner, D. Mertens, F. Kuchenbauer. 2013. Circulating microRNAs in hematological diseases: Principles, challenges, and perspectives. Blood 121:4977–84. doi:10.1182/blood-2013-01-480079.
   PubMed Web of Science ®Google Scholar
• Grasedieck, S., N. Scholer, M. Bommer, J. H. Niess, H. Tumani, A. Rouhi, J. Bloehdorn, P. Liebisch, D. Mertens, H. Döhner, et al. 2012. Impact of serum storage conditions on microRNA stability. Leukemia 26:2414–16. doi:10.1038/leu.2012.106.
   PubMed Web of Science ®Google Scholar
• Hayes, J., P. P. Peruzzi, and S. Lawler. 2014. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol. Med. 20:460–69. doi:10.1016/j.molmed.2014.06.005.
   PubMed Web of Science ®Google Scholar
• Hornung, R. W., and L. D. Reed. 1990. Estimation of average concentration in the presence of nondetectable values. Appl. Occup. Environ. Hyg. 5:46–51. doi:10.1080/1047322X.1990.10389587.
   Google Scholar
• Izumiya, M., N. Tsuchiya, K. Okamoto, and H. Nakagama. 2011. Systematic exploration of cancer-associated microRNA through functional screening assays. Cancer Sci. 102:1615–21. doi:10.1111/j.1349-7006.2011.02007.x.
   PubMed Web of Science ®Google Scholar
• Jansson, M. D., and A. H. Lund. 2012. MicroRNA and cancer. Mol. Oncol. 6:590–610. doi:10.1016/j.molonc.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Kovalova, N., R. Nault, R. Crawford, T. R. Zacharewski, and N. E. Kaminski. 2017. Comparative analysis of TCDD-induced AhR-mediated gene expression in human, mouse and rat primary B cells. Toxicol. Appl. Pharmacol. 316:95–106. doi:10.1016/j.taap.2016.11.009.
   PubMed Web of Science ®Google Scholar
• Kozloski, G. A., X. Jiang, S. Bhatt, J. Ruiz, F. Vega, R. Shaknovich, A. Melnick, I. S. Lossos. 2016. miR-181a negatively regulates NF-kappaB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. Blood 127:2856–66. doi:10.1182/blood-2015-11-680462.
   PubMed Web of Science ®Google Scholar
• Kubiczkova, L., F. Kryukov, O. Slaby, E. Dementyeva, J. Jarkovsky, J. Nekvindova, L. Radova, H. Greslikova, P. Kuglik, E. Vetesnikova, et al. 2014. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 99:511–18. doi:10.3324/haematol.2013.093500.
   PubMed Web of Science ®Google Scholar
• Kyle, R. A., D. R. Larson, T. M. Therneau, A. Dispenzieri, S. Kumar, J. R. Cerhan, S. V. Rajkumar. 2018. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378:241–49. doi:10.1056/NEJMoa1709974.
   PubMed Web of Science ®Google Scholar
• Kyle, R. A., T. M. Therneau, S. V. Rajkumar, D. R. Larson, M. F. Plevak, J. R. Offord, A. Dispenzieri, J. A. Katzmann, L. J. Melton. 2006. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354:1362–69. doi:10.1056/NEJMoa054494.
   PubMed Web of Science ®Google Scholar
• Landgren, O., B. I. Graubard, J. A. Katzmann, R. A. Kyle, I. Ahmadizadeh, R. Clark, S. K. Kumar, A. Dispenzieri, A. J. Greenberg, T. M. Therneau, et al. 2014. Racial disparities in the prevalence of monoclonal gammopathies: A population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28:1537–42. doi:10.1038/leu.2014.34.
   PubMed Web of Science ®Google Scholar
• Landgren, O., R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, et al. 2009. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 113:5412–17. doi:10.1182/blood-2008-12-194241.
   PubMed Web of Science ®Google Scholar
• Landgren, O., Y. K. Shim, J. Michalek. 2015. Agent orange exposure and monoclonal gammopathy of undetermined significance: An operation Ranch Hand veteran cohort study. J. Am. Med. Assoc. Oncol. 1:1061–68.
   Google Scholar
• Landi, M. T., P. A. Bertazzi, A. Baccarelli, D. Consonni, S. Masten, G. Lucier, P. Mocarelli, L. Needham, N. Caporaso, J. Grassman. 2003. TCDD-mediated alterations in the AhR-dependent pathway in Seveso, Italy, 20 years after the accident. Carcinogenesis 24:673–80. doi:10.1093/carcin/bgg002.
   PubMed Web of Science ®Google Scholar
• Lionetti, M., M. Biasiolo, L. Agnelli, K. Todoerti, L. Mosca, S. Fabris, G. Sales, G. L. Deliliers, S. Bicciato, L. Lombardi, et al. 2009. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114:e20–e26. doi:10.1182/blood-2009-08-237495.
   PubMed Web of Science ®Google Scholar
• Liu, N., J. Yang, R. Yuan, J. Peng, L. Liu, and X. Guo. 2019. Effects of mir181a on the biological function of multiple myeloma. Oncol. Rep. 42:291–300. doi:10.3892/or.2019.7160.
   PubMed Web of Science ®Google Scholar
• Liu, Y., B. Yin, C. Zhang, L. Zhou, and J. Fan. 2012. Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. Biochem. Biophys. Res. Commun. 417:371–75. doi:10.1016/j.bbrc.2011.11.119.
   PubMed Web of Science ®Google Scholar
• Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–08. doi:10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Luo, X., J. Zhang, H. Wang, Y. Du, L. Yang, F. Zheng, D. Ma. 2012. PolyA RT-PCR-based quantification of microRNA by using universal TaqMan probe. Biotechnol. Lett. 34:627–33. doi:10.1007/s10529-011-0813-3.
   PubMed Web of Science ®Google Scholar
• Michalek, J., J. Robinson, and K. Fox. 2005. The air force health study: An epidemiologic investigation of health effects in air force personnel following exposure to herbicides. 2002 follow-up examination results. NTIS ADA438835 National Technical Information Service, Springfield, VA.
   Google Scholar
• Mishra, A. K., and D. Dingli. 2019. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia 33:2695–709. doi:10.1038/s41375-019-0470-4.
   PubMed Web of Science ®Google Scholar
• Mitchell, P. S., R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O’Briant, A. Allen, et al. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105:10513–18. doi:10.1073/pnas.0804549105.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. 2018. Veterans and agent orange: Update 11 (2018). Washington, DC: The National Academies Press. doi:10.17226/25137.
   Google Scholar
• Neu, J., P. J. Dziunycz, A. Dzung, K. Lefort, M. Falke, R. Denzler, S. N. Freiberger, G. Iotzova-Weiss, A. Kuzmanov, M. P. Levesque, et al. 2017. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. PLoS ONE 12(9):e0185028. eCollection 2017. doi:10.1371/journal.pone.0185028.
   PubMed Web of Science ®Google Scholar
• Patterson, D. G., Jr., L. Hampton, C. R. Lapeza Jr., W. T. Belser, V. Green, L. Alexander, L. L. Needham. 1987. High-resolution gas chromatographic/high-resolution mass spectrometric analysis of human serum on a whole-weight and lipid basis for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Anal. Chem. 59:2000–05. doi:10.1021/ac00142a023.
   PubMed Web of Science ®Google Scholar
• Pichiorri, F., S. S. Suh, M. Ladetto. 2008. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 105:12885–90.
   PubMed Web of Science ®Google Scholar
• Raveche, E. S., E. Salerno, B. J. Scaglione, V. Manohar, F. Abbasi, Y.-C. Lin, T. Fredrickson, P. Landgraf, S. Ramachandra, K. Huppi, et al. 2007. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109:5079–86. doi:10.1182/blood-2007-02-071225.
   PubMed Web of Science ®Google Scholar
• Roccaro, A. M., A. Sacco, B. Thompson, X. Leleu, A. K. Azab, F. Azab, J. Runnels, X. Jia, H. T. Ngo, M. R. Melhem, et al. 2009. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113:6669–80. doi:10.1182/blood-2009-01-198408.
   PubMed Web of Science ®Google Scholar
• Rokavec, M., H. Li, L. Jiang, and H. Hermeking. 2014. The p53/miR-34a axis in development and disease. J. Mol. Cell Biol. 3:214–30.
   Google Scholar
• Roth, C., B. Rack, V. Muller, W. Janni, K. Pantel, and H. Schwarzenbach. 2010. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12:R90. doi:10.1186/bcr2766.
   PubMed Web of Science ®Google Scholar
• Sethupathy, P., B. Corda, and A. G. Hatzigeorgiou. 2006. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 12:192–97. doi:10.1261/rna.2239606.
   PubMed Web of Science ®Google Scholar
• Slabakova, E., Z. Culig, J. Remsik, and K. Soucek. 2017. Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 8:e3100. doi:10.1038/cddis.2017.495.
   PubMed Web of Science ®Google Scholar
• Sun, C. Y., X. M. She, Y. Qin, Z.-B. Chu, L. Chen, L.-S. Ai, L. Zhang, Y. Hu. 2013. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 34:426–35. doi:10.1093/carcin/bgs333.
   PubMed Web of Science ®Google Scholar
• Villa, M., M. Gialitakis, M. Tolaini, H. Ahlfors, C. J. Henderson, C. R. Wolf, R. Brink, B. Stockinger. 2017. Aryl hydrocarbon receptor is required for optimal B-cell proliferation. Embo J. 36:116–28. doi:10.15252/embj.201695027.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307–10. doi:10.1038/35042675.
   PubMed Web of Science ®Google Scholar
• Wang, L., M. Kumar, Q. Deng, X. Wang, M. Liu, Z. Gong, S. Zhang, X. Ma, Z. Y. Xu-Monette, and M. Xiao, et al. 2019. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer Lett 440-441:135–44. doi: 10.1016/j.canlet.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Wang, W., M. Corrigan-Cummins, E. A. Barber, L. M. Saleh, A. Zingone, A. Ghafoor, R. Costello, Y. Zhang, R. J. Kurlander, N. Korde, et al. 2015. Aberrant levels of miRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression. J. Mol. Diagn. 17:669–78. doi:10.1016/j.jmoldx.2015.06.006.
   PubMed Web of Science ®Google Scholar
• Wang, W., M. Corrigan-Cummins, J. Hudson, I. Maric, O. Simakova, S. S. Neelapu, L. W. Kwak, J. E. Janik, B. Gause, E. S. Jaffe, et al. 2012. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 97:586–94. doi:10.3324/haematol.2011.048132.
   PubMed Web of Science ®Google Scholar
• Weiss, B. M., J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl. 2009. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–22. doi:10.1182/blood-2008-12-195008.
   PubMed Web of Science ®Google Scholar
• Wu, A., K. Wu, J. Li, Y. Mo, Y. Lin, Y. Wang, X. Shen, S. Li, L. Li, Z. Yang, et al. 2015. Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma. J. Transl. Med. 13 (1):105. doi:10.1186/s12967-015-0462-8.
   PubMedGoogle Scholar
• Zhang, D. G., J. N. Zheng, and D. S. Pei. 2014. P53/microRNA-34-induced metabolic regulation: New opportunities in anticancer therapy. Mol. Cancer 13:115. doi:10.1186/1476-4598-13-115.
   PubMed Web of Science ®Google Scholar
• Zhang, J., S. Li, L. Li, M. Li, C. Guo, J. Yao, S. Mi. 2015. Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinf.. 13(1):17–24. doi:10.1016/j.gpb.2015.02.001.
   PubMed Web of Science ®Google Scholar